Metallic nanoparticles for cancer immunotherapy

Simple item page
dc.citation.firstpage673en_US
dc.citation.issueNumber6en_US
dc.citation.journalTitleMaterials Todayen_US
dc.citation.lastpage685en_US
dc.citation.volumeNumber21en_US
dc.contributor.authorEvans, Emily Reiseren_US
dc.contributor.authorBugga, Pallavien_US
dc.contributor.authorAsthana, Vishwaratnen_US
dc.contributor.authorDrezek, Rebekahen_US
dc.contributor.orgBioengineeringen_US
dc.contributor.orgElectrical and Computer Engineeringen_US
dc.date.accessioned2019-01-24T16:07:56Zen_US
dc.date.available2019-01-24T16:07:56Zen_US
dc.date.issued2018en_US
dc.description.abstractCancer immunotherapy, or the utilization of the body’s immune system to attack tumor cells, has gained prominence over the past few decades as a viable cancer treatment strategy. Recently approved immunotherapeutics have conferred remission upon patients with previously bleak outcomes and have expanded the number of tools available to treat cancer. Nanoparticles – including polymeric, liposomal, and metallic formulations – naturally traffic to the spleen and lymph organs and the relevant immune cells therein, making them good candidates for delivery of immunotherapeutic agents. Metallic nanoparticle formulations, in particular, are advantageous because of their potential for dense surface functionalizationand their capability for optical or heat-based therapeutic methods. Many research groups have investigated the potential of nanoparticle-mediated delivery platforms to improve the efficacy of immunotherapies. Despite the significant preclinical successes demonstrated by many of these platforms over the last twenty years, only a few metallic nanoparticles have successfully entered clinical trials with none achieving FDA approval for cancer therapy. In this review, we will discuss preclinical research and clinical trials involving metallic nanoparticles (MNPs) for cancer immunotherapy applications and discuss the potential for clinical translation of MNPs.en_US
dc.identifier.citationEvans, Emily Reiser, Bugga, Pallavi, Asthana, Vishwaratn, et al.. "Metallic nanoparticles for cancer immunotherapy." <i>Materials Today,</i> 21, no. 6 (2018) Elsevier: 673-685. https://doi.org/10.1016/j.mattod.2017.11.022.en_US
dc.identifier.digitalMetallic-nanoparticlesen_US
dc.identifier.doihttps://doi.org/10.1016/j.mattod.2017.11.022en_US
dc.identifier.urihttps://hdl.handle.net/1911/105119en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleMetallic nanoparticles for cancer immunotherapyen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Metallic-nanoparticles.pdf
Size:
1.86 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications